These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 11823042)

  • 1. Nonmyeloablative allogeneic bone marrow transplantation as immunotherapy for hematologic malignancies and metastatic solid tumors in preclinical models.
    Prigozhina TB; Gurevitch O; Morecki S; Yakovlev E; Elkin G; Slavin S
    Exp Hematol; 2002 Jan; 30(1):89-96. PubMed ID: 11823042
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Study on nonmyeloablative allogeneic bone marrow transplantation in the treatment of L615 leukemia mice].
    Xu KL; Ju JP; Pan XY; Du B; Li ZY; Lu QX
    Zhonghua Xue Ye Xue Za Zhi; 2003 Jul; 24(7):372-5. PubMed ID: 12941194
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevention of diabetes in nonobese diabetic mice by nonmyeloablative allogeneic bone marrow transplantation.
    Elkin G; Prigozhina TB; Slavin S
    Exp Hematol; 2004 Jun; 32(6):579-84. PubMed ID: 15183899
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevention of acute graft-vs-host disease by a single low-dose cyclophosphamide injection following allogeneic bone marrow transplantation.
    Prigozhina TB; Elkin G; Khitrin S; Slavin S
    Exp Hematol; 2008 Dec; 36(12):1750-9. PubMed ID: 18809241
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Photochemical treatment of donor lymphocytes inhibited their ability to facilitate donor engraftment or increase donor chimerism after nonmyeloablative conditioning or establishment of mixed chimerism.
    Johnson BD; Taylor PA; Stankowski MC; Talib S; Hearst JE; Blazar BR
    Biol Blood Marrow Transplant; 2002; 8(11):581-7. PubMed ID: 12463476
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Delayed infusion of immunocompetent donor cells after bone marrow transplantation breaks graft-host tolerance allows for persistent antileukemic reactivity without severe graft-versus-host disease.
    Johnson BD; Truitt RL
    Blood; 1995 Jun; 85(11):3302-12. PubMed ID: 7756664
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lymphohematopoietic graft-vs.-host reactions can be induced without graft-vs.-host disease in murine mixed chimeras established with a cyclophosphamide-based nonmyeloablative conditioning regimen.
    Pelot MR; Pearson DA; Swenson K; Zhao G; Sachs J; Yang YG; Sykes M
    Biol Blood Marrow Transplant; 1999; 5(3):133-43. PubMed ID: 10392959
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Eradication of residual disease by administration of leukemia-specific T cells after experimental allogeneic bone marrow transplantation.
    Zeis M; Uharek L; Glass B; Vosskötter W; Dreger P; Schmitz N; Steinmann J
    Exp Hematol; 1998 Oct; 26(11):1068-73. PubMed ID: 9766447
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CD40 ligand-specific antibodies synergize with cyclophosphamide to promote long-term transplantation tolerance across MHC barriers but inhibit graft-vs-leukemia effects of transplanted cells.
    Prigozhina TB; Gurevitch O; Elkin G; Morecki S; Yakovlev E; Slavin S
    Exp Hematol; 2003 Jan; 31(1):81-8. PubMed ID: 12543110
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Depletion of alloantigen-primed lymphocytes overcomes resistance to allogeneic bone marrow in mildly conditioned recipients.
    Prigozhina TB; Elkin G; Gurevitch O; Morecki S; Yakovlev E; Khitrin S; Slavin S
    Blood Cells Mol Dis; 2004; 33(3):238-47. PubMed ID: 15528138
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Delayed infusion of normal donor cells after MHC-matched bone marrow transplantation provides an antileukemia reaction without graft-versus-host disease.
    Johnson BD; Drobyski WR; Truitt RL
    Bone Marrow Transplant; 1993 Apr; 11(4):329-36. PubMed ID: 8485480
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effective graft-versus-leukemia effects independent of graft-versus-host disease after T cell-depleted allogeneic bone marrow transplantation in a murine model of B cell leukemia/lymphoma. Role of cell therapy and recombinant IL-2.
    Weiss L; Lubin I; Factorowich I; Lapidot Z; Reich S; Reisner Y; Slavin S
    J Immunol; 1994 Sep; 153(6):2562-7. PubMed ID: 8077666
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nonmyeloablative conditioning to induce bilateral tolerance after allogeneic bone marrow transplantation in mice.
    Prigozhina TB; Gurevitch O; Slavin S
    Exp Hematol; 1999 Oct; 27(10):1503-10. PubMed ID: 10517491
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Graft-versus-host reactivity and graft-versus-leukemia effect in murine allogeneic bone marrow chimeras conditioned with total body irradiation or total lymphoid irradiation.
    Salam A; Waer M
    Transplantation; 1996 Mar; 61(5):826-30. PubMed ID: 8607190
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Allogeneic cell-mediated immunotherapy for eradication of minimal residual disease: comparison of T-cell and IL-2 activated killer (LAK) cell-mediated adoptive immunotherapy in murine models.
    Vourka-Karussis U; Ackerstein A; Pugatsch T; Slavin S
    Exp Hematol; 1999 Mar; 27(3):461-9. PubMed ID: 10089908
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Depletion of donor-reactive cells as a new concept for improvement of mismatched bone marrow engraftment using reduced-intensity conditioning.
    Prigozhina TB; Elkin G; Khitrin S; Slavin S
    Exp Hematol; 2004 Nov; 32(11):1110-7. PubMed ID: 15539090
    [TBL] [Abstract][Full Text] [Related]  

  • 17. IL-11 separates graft-versus-leukemia effects from graft-versus-host disease after bone marrow transplantation.
    Teshima T; Hill GR; Pan L; Brinson YS; van den Brink MR; Cooke KR; Ferrara JL
    J Clin Invest; 1999 Aug; 104(3):317-25. PubMed ID: 10430613
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
    Petersen SL
    Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bidirectional immune tolerance in nonmyeloablative MHC-mismatched BMT for murine β-thalassemia.
    E S; Seth A; Vogel P; Sommers M; Ong T; Pillai AB
    Blood; 2017 Jun; 129(22):3017-3030. PubMed ID: 28351935
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases.
    Slavin S; Nagler A; Naparstek E; Kapelushnik Y; Aker M; Cividalli G; Varadi G; Kirschbaum M; Ackerstein A; Samuel S; Amar A; Brautbar C; Ben-Tal O; Eldor A; Or R
    Blood; 1998 Feb; 91(3):756-63. PubMed ID: 9446633
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.